Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia

References

• Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11-26S
   PubMed Web of Science ®Google Scholar
• Cazzola M, Beguin Y, Kloczko J. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-93
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82
   PubMed Web of Science ®Google Scholar
• Osterborg A, Brandberg Y, Molostova V. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94
   PubMed Web of Science ®Google Scholar
• Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-34
   PubMed Web of Science ®Google Scholar
• Witzig TE, Silberstein PT, Loprinzi CL. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products. Geneva: WHO, 2006
   Google Scholar
• European Medicines Agency (EMEA). Guideline on Similar Biological Medicinal Products (CHMP/437/04, 1-7). London: EMEA, 2005
   Google Scholar
• European Directorate for the Quality of Medicine (EDQM). Erythropoietin Concentrated Solution, European Pharmacopoeia 6.0. Strasbourg: EDQM, 2008:1813-17
   Google Scholar
• European Generics Medicines Association (EGA). Frequently asked questions about biosimilar medicines. Available at: http://www.egagenerics.com/FAQ-biosimilars.htm [Last accessed 4 December 2008]
   Google Scholar
• Abels RI, Larholt KM, Krantz KD. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1996;1:140-50
   PubMedGoogle Scholar
• Rosenzweig MQ, Bender CM, Lucke JP. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-90
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Information on erythropoiesis stimulating agents (ESA) (marketed as Procrit, Epogen, and Aranesp). Available at: http://www.egagenerics.com/FAQ-biosimilars.htm [Last accessed 4 December 2008]
   Google Scholar
• European Medicines Agency (EMEA). Public statement: European Medicines Agency starts review of the safety of epoetins (EMEA/188068/2007, 1-2). London: EMEA, 2007
   Google Scholar
• European Medicines Agency (EMEA). EPAR for Retacrit, Annex I: Summary of Product Characteristics. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/retacrit/H-872-PI-en.pdf [Last accessed 19 April 2009]
   Google Scholar
• Bokemeyer C, Aapro M, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
   PubMed Web of Science ®Google Scholar
• Spaëth D, Desablens B, Rodon P. Epoetin β once-weekly therapy in anemic patients with solid tumours and non-myeloid hematological malignancies receiving chemotherapy. Oncology 2008;74:112-18
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25
   PubMed Web of Science ®Google Scholar
• Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-9
   PubMed Web of Science ®Google Scholar
• Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(Suppl 7):43-6
   PubMedGoogle Scholar
• Glaspy J. Anemia and fatigue in cancer patients. Cancer Suppl 2001;92:1719-24
   PubMed Web of Science ®Google Scholar